Substituted pyrazoles as novel selective ligands for the human dopamine D 4 receptor
摘要:
Two novel series of 3-(heterocyclylmethyl)pyrazoles have been synthesised and evaluated as ligands for the human dopamine D-4 receptor. Compounds in series I (exemplified by 8k) have a phenyl ring joined to the 4-position of the pyrazole while those in series II (exemplified by 15j) have a 5-phenyl ring linked by a saturated chain to the 4-position of the pyrazole. Both series supplied compounds with excellent affinity for the human D-4 and good selectivity over other dopamine receptors. Excellent selectivity over calcium, sodium, and potassium ion channels was also achieved. (C) 1998 Elsevier Science Ltd. All rights reserved.
Fused tricyclic heteroaromatic derivatives as dopamine receptor subtype
申请人:Merck, Sharp & Dohme, Ltd.
公开号:US05686480A1
公开(公告)日:1997-11-11
A class of fused tricyclic heteroaromatic compounds of formula (I), or a salt thereof or a prodrug thereof containing a fused pyrazole ring are ligands for dopamine receptor subtypes within the body and are therefore of use in the treatment and/or prevention of disorders of the dopamine system, such as schizophrenia.
[EN] FUSED TRICYCLIC HETEROAROMATIC DERIVATIVES AS DOPAMINE RECEPTOR SUBTYPE LIGANDS<br/>[FR] DERIVES HETEROAROMATIQUES TRICYCLIQUES FUSIONNES UTILISES EN TANT QUE LIGANDS DE SOUS-TYPES DE RECEPTEUR DE LA DOPAMINE
申请人:MERCK SHARP & DOHME LIMITED
公开号:WO1995007262A1
公开(公告)日:1995-03-16
(EN) A class of fused tricyclic heteroaromatic compounds of formula (I), or a salt thereof or a prodrug thereof containing a fused pyrazole ring are ligands for dopamine receptor subtypes within the body and are therefore of use in the treatment and/or prevention of disorders of the dopamine system, such as schizophrenia.(FR) Une classe de composés hétéroaromatiques tricycliques fusionnés de formule (I) ou un de leurs sel ou promédicaments, contenant un cycle pyrazole fusionné, sont des ligands de sous-types de récepteur de la dopamine dans le corps, et s'avèrent donc utiles dans le traitement et/ou la prévention des troubles du système dopaminergique, comme la schizophrénie.